dc.contributor.author | Yalcintepe, Sinem | |
dc.contributor.author | Ozdemir, Ozturk | |
dc.contributor.author | Silan, Coskun | |
dc.contributor.author | Ozen, Filiz | |
dc.contributor.author | Uludag, Ahmet | |
dc.contributor.author | Candan, Ferhan | |
dc.contributor.author | Silan, Fatma | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:45:21Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:45:21Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0378-7966 | |
dc.identifier.issn | 2107-0180 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s13318-015-0255-8 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/7312 | |
dc.description | WOS: 000376250700009 | en_US |
dc.description | PubMed ID: 25645282 | en_US |
dc.description.abstract | The cytochrome P450 2D6 (CYP2D6) is a cytochrome P450 enzyme involved in the oxidative biotransformation of the xenobiotics, carcinogens and various clinically important drugs. Patients are evaluated in three sub-groups of extensive (EM), intermediate (IM) and poor metabolizer (PM) phenotypes due to their drug-metabolising ability for the target CYP2D6 gene. Colchicine non-responsive FMF patients were prospectively genotyped for the major CYP2D6 alleles in the current study. Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods. DNA banks isolated from blood-EDTA were retrospectively used in the current patients and results were compared statistically. Increased CYP2D6 *4 and *6 allele frequencies were highly detected in the colchicine non-responsive FMF patients when compared to the responsive group. Results showed the frequencies of major CYP2D6 *1(wild), *3(2637A > delA), *4(G1934A), *5(total gene deletion) and *6(1707T del) alleles in 0.550, 0.042, 0.158, 0.025 and 0.225 for non-responder and 0.880 and 0.120 (CYP2D6*1 and *4) for the responder groups, respectively. Despite small sample size, this study suggests that there is an association between CYP2D6*4 and CYP2D6*6 alleles and drug intoxicants in colchicine non-responder FMF patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SPRINGER FRANCE | en_US |
dc.relation.isversionof | 10.1007/s13318-015-0255-8 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CYP2D6 polymorphism | en_US |
dc.subject | Colchicine resistance | en_US |
dc.subject | FMF | en_US |
dc.subject | Pharmacogenetics | en_US |
dc.title | The CYP4502D6*4 and*6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients | en_US |
dc.type | article | en_US |
dc.relation.journal | EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS | en_US |
dc.contributor.department | [Yalcintepe, Sinem -- Ozdemir, Ozturk -- Uludag, Ahmet -- Silan, Fatma] Canakkale Onsekiz Mart Univ, Fac Med, Dept Med Genet, TR-17100 Canakkale, Turkey -- [Yalcintepe, Sinem] Adana Numune Educ & Res Hosp, Dept Med Genet, Adana, Turkey -- [Ozdemir, Ozturk -- Ozen, Filiz] Cumhuriyet Univ, Fac Med, Dept Med Genet, Sivas, Turkey -- [Silan, Coskun] Canakkale Onsekiz Mart Univ, Fac Med, Dept Pharmacol, Canakkale, Turkey -- [Candan, Ferhan] Cumhuriyet Univ, Fac Med, Dept Nephrol, Sivas, Turkey | en_US |
dc.identifier.volume | 41 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.endpage | 286 | en_US |
dc.identifier.startpage | 281 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |